ArticleScience immunology2024
Two-dose priming immunization amplifies humoral immunity by synchronizing vaccine delivery with the germinal center response.
Erratum issuedAbstract read
In one paragraph
Article in Science immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 25 papers.
0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Harnessing mucosal immunity for protective vaccines.Nature reviews. Immunology · 2026Review
- Rapid boosting increases germinal center responses to sequential vaccines.Nature immunology · 2026Article
- Engineering drug-responsive replication machinery for precise control of self-amplifying RNA.Nature biomedical engineering · 2026Article
- Atomic layer deposition for core-shell microparticle vaccines enabling programmable antigen delivery to lymph nodes enhance humoral immune responses.bioRxiv : the preprint server for biology · 2026Article
- Review
- Rapidly acquired HIV-1 neutralization breadth in a rhesus V2 apex knockin mouse model after a single bolus immunization.Science immunology · 2026Article
- Subunit vaccination using Atomic Layering Thermostable Antigen and Adjuvant (ALTAFrontiers in immunology · 2026Article
- Germline-Targeting Strategies to Induce bNAbs against HIV-1.Current HIV research · 2026Review
- Article
- Beyond monotherapy: Combination therapies for HIV-1 cure through joint application of neutralizing antibodies, genome editing, and reservoir management.Infectious medicine · 2025Review
- Mechanism for evolution of diverse autologous antibodies upon broadly neutralizing antibody therapy of people with HIV.Cell reports · 2025Article
- Article
- Article
- Consistent Induction of Broadly Neutralizing HIV Antibodies by a Novel Two-Step Mechanism Informs Immunogen Design.bioRxiv : the preprint server for biology · 2025Article
- Article
- Naringenin as a phytogenic adjuvant systematically enhances the protective efficacy of H9N2 inactivated vaccine through coordinated innate-adaptive immune priming in chickens.Poultry science · 2025Article
- Rapid acquisition of HIV-1 neutralization breadth in a rhesus V2 apex germline antibody mouse model after a single bolus immunization.bioRxiv : the preprint server for biology · 2025Article
- Engineering gene expression dynamics via self-amplifying RNA with drug-responsive non-structural proteins.bioRxiv : the preprint server for biology · 2025Article
- Harnessing Thalassochemicals: Marine Saponins as Bioactive Agents in Nutraceuticals and Food Technologies.Marine drugs · 2025Review
- Nanoscale Biodegradable Printing for Designed Tuneability of Vaccine Delivery Kinetics.Advanced materials (Deerfield Beach, Fla.) · 2025Article
Corrections and comments
- Erratum issued
- Update of
Authors and funding
13 authors.
Sachin H BhagchandaniDepartment of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.ORCID 0000-0003-4410-5800
Leerang YangDepartment of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.ORCID 0000-0002-7819-4381
Jonathan H LamKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA 02139, USA.ORCID 0000-0002-2811-7177
Laura MaiorinoDepartment of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.ORCID 0000-0001-8217-1337
Elana Ben-AkivaDepartment of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.ORCID 0000-0003-1085-5902
Kristen A RodriguesDepartment of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.ORCID 0000-0002-0680-9834
Anna RomanovDepartment of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.ORCID 0000-0002-1239-4946
Heikyung SuhKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA 02139, USA.ORCID 0000-0003-0787-298X
Aereas AungDepartment of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.
Shengwei WuKoch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, 500 Main Street, Cambridge, MA 02139, USA.ORCID 0000-0001-8175-3490
Anika WadheraDepartment of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.ORCID 0009-0009-4694-6129
Arup K ChakrabortyDepartment of Chemical Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.ORCID 0000-0003-1268-9602
Darrell J IrvineDepartment of Biological Engineering, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Cambridge, MA 02139, USA.ORCID 0000-0002-8637-1405
Funding
Identification of neutralizing epitopes on SARS-CoV-2 spike for design of vaccines and small-molecule antiviralsUM1AI144462 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI BURTON, DENNIS R. · 2019 to 2025
$201.6MVIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Jacqueline A. Lees · 1985 to 2026
$93.9MUsing a tonsil organoid system to probe conditions for the induction of protective antibody and T cell responses to influenza.U19AI057229 · NIAID · STANFORD UNIVERSITY · PI Mark Morris Davis · 2003 to 2026
$88.5MMaximizing germinal centers and somatic hypermutation to HIV Env immunogensR37AI125068 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI Shane P Crotty, Darrell J Irvine · 2021 to 2026
$5.4MMaximizing germinal centers and somatic hypermutation to HIV Env immunogensR01AI125068 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI CROTTY, SHANE P, IRVINE, DARRELL J · 2016 to 2020
$4.3MImmune engineering of optimized sequential immunization strategies for HIV vaccinesR33AI161297 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI CROTTY, SHANE P, IRVINE, DARRELL J · 2024 to 2025
$2.5MImmune engineering of optimized sequential immunization strategies for HIV vaccinesR61AI161297 · NIAID · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CROTTY, SHANE P, IRVINE, DARRELL J · 2021 to 2023
$2.3M"Extended dosing" immunization to enhance humoral immunity to next-generation vaccinesR01AI175489 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Darrell J Irvine · 2023 to 2026
$1.9MToward safe, systemic immunotherapies for treatment of metastatic disease: Developing dendritic cell-biased immunomodulators with precise control over magnitude and timing of immune stimulationF99CA264404 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI BHAGCHANDANI, SACHIN · 2021 to 2022
$93kHoward Hughes Medical InstituteNCI NIH HHS F99 CA264404NCI NIH HHS P30 CA014051NIAID NIH HHS R01 AI125068NIAID NIH HHS R01 AI175489NIAID NIH HHS R33 AI161297NIAID NIH HHS R37 AI125068NIAID NIH HHS R61 AI161297NIAID NIH HHS U19 AI057229NIAID NIH HHS UM1 AI144462
Abstract
Prolonging exposure to subunit vaccines during the primary immune response enhances humoral immunity. Escalating-dose immunization (EDI), administering vaccines every other day in an increasing pattern over 2 weeks, is particularly effective but challenging to implement clinically. Here, using an HIV Env trimer/saponin adjuvant vaccine, we explored simplified EDI regimens and found that a two-shot regimen administering 20% of the vaccine followed by the remaining 80% of the dose 7 days later increased T
Indexed as
Germinal CenterImmunity, HumoralAIDS VaccinesAnimalsB-LymphocytesFemaleMiceMice, Inbred C57BLVaccines, SubunitAIDS VaccinesVaccines, Subunit
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.